Targeting Cancer Stem Cells May Lower Relapse Rates, Early Research Suggests

Targeting Cancer Stem Cells May Lower Relapse Rates, Early Research Suggests
Histone deacetylase (HDAC) inhibitors, which prevent epigenetic modifications in the DNA, may be able to eliminate cancer stem cells (CSCs) in ovarian and breast cancers, making relapses less likely after standard-of-care treatments, researchers report. The study, “Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer,” published in Oncogene,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *